[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP. Rothe A, et al. Int J Cancer. 2014 Jun 15;134(12):2829-40. doi: 10.1002/ijc.28609. Epub 2013 Nov 29. Int J Cancer. 2014. PMID: 24242212
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners KS, Marie M, von Strandmann EP, Rothe A. Jachimowicz RD, et al. Among authors: rothe a. Mol Cancer Ther. 2011 Jun;10(6):1036-45. doi: 10.1158/1535-7163.MCT-10-1093. Epub 2011 Apr 27. Mol Cancer Ther. 2011. PMID: 21525185
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.
Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A. Pogge von Strandmann E, et al. Among authors: rothe a. Immunity. 2007 Dec;27(6):965-74. doi: 10.1016/j.immuni.2007.10.010. Epub 2007 Dec 6. Immunity. 2007. PMID: 18055229 Free article.
Multi-specific antibodies for cancer immunotherapy.
Jachimowicz RD, Borchmann S, Rothe A. Jachimowicz RD, et al. Among authors: rothe a. BioDrugs. 2014 Aug;28(4):331-43. doi: 10.1007/s40259-014-0091-4. BioDrugs. 2014. PMID: 24638872 Review.
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A. Rothe A, et al. Blood. 2015 Jun 25;125(26):4024-31. doi: 10.1182/blood-2014-12-614636. Epub 2015 Apr 17. Blood. 2015. PMID: 25887777 Free PMC article. Clinical Trial.
119 results